TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Peer referrals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Help-seeking rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hiccup intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time spent in the hypoglycemic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of hypoglycemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for carbohydrate treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-perception of non-improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pancreatic-fat loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCRIP score at 360 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for respiratory support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Need for intravenous fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for antibiotic use
Endpoint domain: Adverse events/effects
Primary endpoint: New or progressive multiple-organ dysfunction syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete circumferential spread of LA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of LA used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accelerated clinical healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of palatal donor sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End-stage renal disease (ESRD)
Endpoint domain: Mortality/survival
Primary endpoint: Serum creatinine increase of 50% or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Esthetic result rating
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Discriminative power of the SDH score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the SDH score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the SDH score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer training trials to reach proficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieved human chorionic gonadotropin detected pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: absolute bioavailability of MPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of hysterosonography for diagnosing polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of hysterosonography for diagnosing synechiae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of hysterosonography for diagnosing submucous myoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of osteointegration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat metabolism enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood viscosity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peripheral hypervascularity of the corpus luteum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of unintentional leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Comfort rating of masks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AUC 0-24 estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dietary behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of uterine contractility response to oxytocin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myocardial infarction or death from coronary heart disease
Endpoint domain: Mortality/survival
Primary endpoint: troponin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Obesity indices improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood lipid indices improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DHP-18 total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 'health change'
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DHP-18 'disinhibited eating'
Endpoint domain: Adverse events/effects
Primary endpoint: estimated VO2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of calories from fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rigidity of posts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of posts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late distant recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Increase in step counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean postvaccination neutralizing antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of subjects with > or =4‐fold increases in neutralizing titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean improvement in angiokeratoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Colonization with infecting strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: NRS (Numeric Rating Scale) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose level (mean peak, mmol/l)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin level (mean peak, mU/l)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: posttraumatic stress disorder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular pressure measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of covered tonometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of covered tonometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life - Physical Dimension
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of Life - Environment Dimension
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Work Ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Median total cost burden
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Median DCB
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Median DCBi
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Glucose concentration improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Forward movement of the maxilla
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in SNA, ANB, UL-EP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet expression of CD40 ligand (CD40L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of platelet‐leukocyte conjugates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Plasma von Willebrand factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement in hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Degree of conviction about an arbitrary statement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: WBC reduction to < 1 x 10(6) WBCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelet yield standards
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: cumulative pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of days of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: analgesic consumption score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bacterial infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hospital days with fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary tract infections after catheter removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: fat-free body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of intubation and mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: myocardial no-reflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bloating, distension, and discomfort symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall digestive comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Anxiety at baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: blood glucose variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma fibrinogen concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patient satisfaction with nurse practitioner consultations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ETSE (Emotional and Threatening Situational Experience)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incremental cost-effectiveness ratio (ICER) of ticagrelor
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Development of symptomatic lymphoceles requiring treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Need for invasive procedures to treat lymphoceles
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence of fluid collections in the fifth postoperative week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite of doubling of serum creatinine, ESRD, or death
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative cardiac mortality
Endpoint domain: Mortality/survival
Primary endpoint: Systolic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Healthy Eating Index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: complete wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: client readiness to change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: therapeutic relationship features
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: treatment outcome for disordered eating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reductions in danger
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reductions in disgust
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: nutritive blood flow response to a subsequent meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: antilipolytic response to meals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of VT/VF
Endpoint domain: Mortality/survival
Primary endpoint: Risk of VT/VF or death
Endpoint domain: Mortality/survival
Primary endpoint: Daytime sleep propensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep stages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquisition of cutaneous leishmaniasis (CL)
Endpoint domain: Adverse events/effects
Primary endpoint: blood urea nitrogen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma free amino acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient-centeredness of contraceptive counseling
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: prevalence of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvement in motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Locoregional recurrence (LRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peritoneal carcinomatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in cravings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interest in quitting post-discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: macular swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean sleep duration per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily energy purchased
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analog scoring scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in pain from baseline to endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving ≥30% and ≥50% reductions in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGIC scores at endpoint
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximal drug concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morning PEF changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bone coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Halitosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS ≤2.4 after re-introduction of infliximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint damage progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cessation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain-free relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: blood product usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Motor Unified Parkinson's Disease Rating Scale (UPDRS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preterm labor incidence
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of serous retinopathy
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of pyrexia
Endpoint domain: Adverse events/effects
Primary endpoint: Physical health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: neurological functional deficit scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fugl-Meyer score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in care provided by nurses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change from baseline to initial disability worsening in EDSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pure tone average
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speech recognition thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD catheter‐associated infections
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment choice preferences
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Life expectancy reduction due to severe NDI
Endpoint domain: Mortality/survival
Primary endpoint: Quality-adjusted life years (QALYs) lost due to severe NDI
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Healthcare costs associated with severe NDI
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Risk of 10-fold error for bolus medications
Endpoint domain: Adverse events/effects
Primary endpoint: Prescribing errors for medications administered by infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Mechanical hyperalgesia area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tonic pressure pain ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First Progression-Free Survival (1st PFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Control Rate (TCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPI score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPI-Distress score improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma alpha-tocopherol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in oxygenation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of END and RIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: reduction of vaginal pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Median time to symptomatic progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of metastatic prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Detection rate of localized prostate cancer by PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first-attempt success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State anxiety inventory scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: percent total absent days
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: percent illness‐related absent days
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cardiovascular risk profile improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MUAC (Mid-Upper Arm Circumference)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in trainee performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on severe contrast reaction simulation scenario test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to lesion healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum lesion area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily assessments of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total control of acute vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes